351 related articles for article (PubMed ID: 11085894)
21. Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and in vitro receptor autoradiography.
Suzuki M; Hatano K; Sakiyama Y; Kawasumi Y; Kato T; Ito K
Synapse; 2001 Sep; 41(4):285-93. PubMed ID: 11494399
[TBL] [Abstract][Full Text] [Related]
22. Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex.
Flores G; Wood GK; Liang JJ; Quirion R; Srivastava LK
J Neurosci; 1996 Nov; 16(22):7366-75. PubMed ID: 8929443
[TBL] [Abstract][Full Text] [Related]
23. D1- and D2-like dopamine receptors are co-localized on the presynaptic varicosities of striatal and nucleus accumbens neurons in vitro.
Wong AC; Shetreat ME; Clarke JO; Rayport S
Neuroscience; 1999 Mar; 89(1):221-33. PubMed ID: 10051231
[TBL] [Abstract][Full Text] [Related]
24. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Mela F; Marti M; Bido S; Cenci MA; Morari M
Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
[TBL] [Abstract][Full Text] [Related]
25. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
26. Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Rite I; Machado A; Cano J; Venero JL
Exp Neurol; 2005 Mar; 192(1):142-55. PubMed ID: 15698628
[TBL] [Abstract][Full Text] [Related]
27. Huntington's disease progression. PET and clinical observations.
Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
[TBL] [Abstract][Full Text] [Related]
28. Effect of desipramine during infancy and preweanling on dorsal striatal dopamine D1 and D2 receptor binding in adolescence in the rat.
Hilakivi I; Rinne J; Marjamäki P
Pol J Pharmacol; 1999; 51(4):311-6. PubMed ID: 10540962
[TBL] [Abstract][Full Text] [Related]
29. Sequential changes of dopaminergic receptors in the rat brain after 6-hydroxydopamine lesions of the medial forebrain bundle.
Araki T; Tanji H; Kato H; Itoyama Y
J Neurol Sci; 1998 Oct; 160(2):121-7. PubMed ID: 9849794
[TBL] [Abstract][Full Text] [Related]
30. Temporal changes of dopaminergic and glutamatergic receptors in 6-hydroxydopamine-treated rat brain.
Araki T; Tanji H; Kato H; Imai Y; Mizugaki M; Itoyama Y
Eur Neuropsychopharmacol; 2000 Sep; 10(5):365-75. PubMed ID: 10974608
[TBL] [Abstract][Full Text] [Related]
31. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
32. Intrastriatal microinjection of sodium nitroprusside induces cell death and reduces binding of dopaminergic receptors.
Yanamoto K; Hosoi R; Uesaka Y; Abe K; Tsukada H; Inoue O
Synapse; 2003 Nov; 50(2):137-43. PubMed ID: 12923816
[TBL] [Abstract][Full Text] [Related]
33. [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases.
Döbrössy MD; Braun F; Klein S; Garcia J; Langen KJ; Weber WA; Nikkhah G; Meyer PT
Nucl Med Biol; 2012 Oct; 39(7):1077-80. PubMed ID: 22591915
[TBL] [Abstract][Full Text] [Related]
34. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
[TBL] [Abstract][Full Text] [Related]
35. Apparent dopamine D1 and D2 receptors in the weaver mutant mouse: receptor binding and coupling to adenylyl cyclase.
Dewar KM; Paquet M; Sequeira A
J Neural Transm (Vienna); 1999; 106(5-6):487-97. PubMed ID: 10443552
[TBL] [Abstract][Full Text] [Related]
36. Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390.
Yu J; Coirini H; Källström L; Wiesel FA; Johnson AE
Synapse; 1998 Sep; 30(1):38-48. PubMed ID: 9704879
[TBL] [Abstract][Full Text] [Related]
37. Time course of the neuroprotective effect of transplantation on quinolinic acid-induced lesions of the striatum.
Levivier M; Gash DM; Przedborski S
Neuroscience; 1995 Nov; 69(1):43-50. PubMed ID: 8637631
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D1 and D2 receptor selectivities of phenyl-benzazepines in rhesus monkey striata.
Weed MR; Woolverton WL; Paul IA
Eur J Pharmacol; 1998 Nov; 361(1):129-42. PubMed ID: 9851550
[TBL] [Abstract][Full Text] [Related]
39. D-1 dopamine receptor changes after striatal quinolinic acid lesion.
Barone P; Tucci I; Parashos SA; Chase TN
Eur J Pharmacol; 1987 Jun; 138(1):141-5. PubMed ID: 2957219
[TBL] [Abstract][Full Text] [Related]
40. Localization of dopamine receptors and associated mRNA in transplants of human fetal striatal tissue in rodents with experimental Huntington's disease.
Pundt LL; Narang N; Kondoh T; Low WC
Neurosci Res; 1997 Apr; 27(4):305-15. PubMed ID: 9152043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
